4:51 PM
 | 
Jan 27, 2014
 |  BC Extra  |  Company News

Medigene acquires cancer immunotherapy play Trianta

Medigene AG (Xetra:MDG1) acquired Trianta Immunotherapies GmbH (Planegg-Martinsried, Germany) in a deal worth up to EUR 9.5 million ($13.1 million). Trianta was spun out of German research center Helmholtz Zentrum Muenchen late last year. Medigene gains three...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >